1Paul R.Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma.J Nucl Med,1987,28:288-292.
2Wu X,Dastidar P,Pertovaara H,et al.Early Treatment Response Evaluation in Patients with Diffuse Large B-Cell Lymphoma-A Pilot Study Comparing Volumetric MRI and PET/CT.Mol Imaging Biol,2010,25(8):22-24.
3Pelosi E,Penna D,Deandreis D,et al.FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.Q J Nucl Med Mol Imaging,2008,52(1):9-16.
4De Jong PA,van Ufford HM,Baarslag HJ,et al.CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma.AJR Am J Roentgenol,2009,192(3):745-53.
5Hutchings M,Specht L.PET/CT in the management of haematological malignancies.Eur J Haematol,2008,80:369-380.
6Mikhaeel NG,Hntchings M,Fields PA,et al.FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.Ann Oncol,2005,16:1514-1523.
7Haioun C,Itti E,Rahmouni A,et al.[18F] fluoro-2-deoxy-D-glucose positron emission tomography(FDGPET)in aggressive lymphoma:an early prognostic tool for predicting patient outcome.Blood,2005,106:1376-1381.
8Kostakoglu L,Goldsmith SJ,Leonard JP,et al.FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.Cancer,2006,107:2678-2687.
9Hutchings M,Mikhaeel NG,Fields PA,et al.Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.Ann Oncol,2005,16:1160-1168.
10Hntchings M,Loft A,Hansen M,et al.FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.Blood,2006,107:52-59.
